Boule Diagnostics Balance Sheet Health
Financial Health criteria checks 1/6
Boule Diagnostics has a total shareholder equity of SEK173.0M and total debt of SEK190.2M, which brings its debt-to-equity ratio to 109.9%. Its total assets and total liabilities are SEK495.0M and SEK322.0M respectively. Boule Diagnostics's EBIT is SEK79.3M making its interest coverage ratio 7. It has cash and short-term investments of SEK20.0M.
Key information
109.94%
Debt to equity ratio
SEK 190.20m
Debt
| Interest coverage ratio | 7x |
| Cash | SEK 20.00m |
| Equity | SEK 173.00m |
| Total liabilities | SEK 322.00m |
| Total assets | SEK 495.00m |
Recent financial health updates
We Think Boule Diagnostics (STO:BOUL) Has A Fair Chunk Of Debt
Apr 10
Does Boule Diagnostics (STO:BOUL) Have A Healthy Balance Sheet?
Oct 10We Think Boule Diagnostics (STO:BOUL) Can Stay On Top Of Its Debt
Mar 06Recent updates
We Think Boule Diagnostics (STO:BOUL) Has A Fair Chunk Of Debt
Apr 10Improved Revenues Required Before Boule Diagnostics AB (publ) (STO:BOUL) Stock's 26% Jump Looks Justified
Dec 03Does Boule Diagnostics (STO:BOUL) Have A Healthy Balance Sheet?
Oct 10Boule Diagnostics AB (publ) Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
Jul 25Capital Allocation Trends At Boule Diagnostics (STO:BOUL) Aren't Ideal
Jul 24Sentiment Still Eluding Boule Diagnostics AB (publ) (STO:BOUL)
Jun 06Results: Boule Diagnostics AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates
May 10Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate
Mar 20Here's What Analysts Are Forecasting For Boule Diagnostics AB (publ) (STO:BOUL) After Its Yearly Results
Feb 09Boule Diagnostics AB (publ) (STO:BOUL) Screens Well But There Might Be A Catch
Dec 30Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital
Jul 25Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 49% Below Their Intrinsic Value Estimate
May 26Boule Diagnostics' (STO:BOUL) Solid Profits Have Weak Fundamentals
Jul 26Returns On Capital Signal Tricky Times Ahead For Boule Diagnostics (STO:BOUL)
Jul 19We Think Boule Diagnostics (STO:BOUL) Can Stay On Top Of Its Debt
Mar 06Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital
Feb 03The Returns At Boule Diagnostics (STO:BOUL) Aren't Growing
Apr 29Should You Investigate Boule Diagnostics AB (publ) (STO:BOUL) At kr67.70?
Apr 09Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Mar 25Consider This Before Buying Boule Diagnostics AB (publ) (STO:BOUL) For The 1.0% Dividend
Mar 07Is Boule Diagnostics' (STO:BOUL) 210% Share Price Increase Well Justified?
Feb 17
Financial Position Analysis
Short Term Liabilities: BOUL's short term assets (SEK252.9M) do not cover its short term liabilities (SEK259.0M).
Long Term Liabilities: BOUL's short term assets (SEK252.9M) exceed its long term liabilities (SEK63.0M).
Debt to Equity History and Analysis
Debt Level: BOUL's net debt to equity ratio (98.4%) is considered high.
Reducing Debt: BOUL's debt to equity ratio has increased from 31% to 109.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if BOUL has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BOUL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/14 18:40 |
| End of Day Share Price | 2025/05/14 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Boule Diagnostics AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| null null | ABG Sundal Collier Sponsored |
| Christian Lee | Pareto Securities |